Legal Representation
Attorney
Fidel Nwamu
USPTO Deadlines
Next Renewal Deadline
1086 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-06-28)
Due Date
June 28, 2028
Grace Period Ends
December 28, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 28, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jun 28, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| May 21, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| May 20, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 20, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 20, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 20, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Feb 11, 2022 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Feb 11, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Feb 11, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jan 25, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Jan 21, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Jan 21, 2022 | IUAF | S | USE AMENDMENT FILED |
| Sep 3, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sep 2, 2021 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Sep 1, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Aug 12, 2021 | NREV | E | NOTICE OF REVIVAL - E-MAILED |
| Aug 11, 2021 | PROA | I | TEAS PETITION TO REVIVE RECEIVED |
| Aug 11, 2021 | PETG | O | PETITION TO REVIVE-GRANTED |
| Aug 11, 2021 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION |
| Jul 22, 2021 | EXT5 | S | SOU EXTENSION 5 FILED |
| Jun 23, 2021 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Jan 23, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jan 21, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jan 21, 2021 | EXT4 | S | SOU EXTENSION 4 FILED |
| Jan 21, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Aug 5, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Aug 5, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Aug 5, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 17, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 15, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 15, 2020 | EXT3 | S | SOU EXTENSION 3 FILED |
| Jul 15, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Dec 14, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Dec 12, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 12, 2019 | EXT2 | S | SOU EXTENSION 2 FILED |
| Dec 12, 2019 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Mar 27, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 25, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 25, 2019 | EXT1 | S | SOU EXTENSION 1 FILED |
| Mar 25, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Jan 22, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Nov 27, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Nov 27, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Nov 7, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Oct 25, 2018 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Oct 21, 2018 | ALIE | A | ASSIGNED TO LIE |
| Oct 9, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Oct 5, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Oct 4, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Detailed Classifications
Class 042
Conducting evaluations in the field of pharmaceuticals; pharmaceutical product development and evaluation services; pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients
First Use Anywhere:
Sep 17, 2016
First Use in Commerce:
Sep 17, 2016
Class 044
healthcare
First Use Anywhere:
Mar 18, 2019
First Use in Commerce:
Mar 18, 2019
Classification
International Classes
042
044